GSTM1 and paroxysmal nocturnal hemoglobinuria: Another study is ongoing in PNH patients with inadequate response (defined as Hb level <10 g/L and/or the need for red blood cell transfusion) to eculizumab (PHAROAH study; NCT02264639); in this phase Ib trial APL-2 is investigated as add-on therapy on top of eculizumab (116).